Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 19/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17195445 | 0.90 | DGAT1 (0.50) | DGAT1 | |
| SCHEMBL17195449 | 0.89 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL15711521 | 0.89 | DGAT1 (0.45) | DGAT1 | |
| SCHEMBL17195441 | 0.86 | DGAT1 (0.52) | DGAT1 | |
| SCHEMBL15690595 | 0.85 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL15690468 | 0.82 | SMN1; SMN2 (0.42) | DGAT1 | |
| SCHEMBL17195452 | 0.82 | DGAT1 (0.61) | DGAT1 | |
| SCHEMBL15711520 | 0.79 | DGAT1 (0.50) | DGAT1 | |
| SCHEMBL17195454 | 0.79 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL15711515 | 0.79 | DGAT1 (0.54) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624174-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160068487-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-10 | — | — | US | disclosed |
| US-9221766-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150299138-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299138-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885DHODH 588/4885 |
| US-20160068487-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885DHODH 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.